These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38607232)

  • 21. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
    Chun SW; Somers ME; Burgener EB
    Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
    Edmondson C; Course CW; Doull I
    Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
    Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
    Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
    Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A
    Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767
    [No Abstract]   [Full Text] [Related]  

  • 28. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
    Yule A; Ng C; Recto A; Lockwood F; Dellschaft NS; Hoad CL; Zagoya C; Mainz JG; Major G; Barr HL; Gowland PA; Stewart I; Marciani L; Spiller RC; Smyth AR
    J Cyst Fibros; 2024 Sep; 23(5):984-990. PubMed ID: 39242338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment.
    Morgan SJ; Coulter E; Betts HL; Solomon GM; Clancy JP; Rowe SM; Nichols DP; Singh PK;
    J Clin Invest; 2024 Sep; 134(20):. PubMed ID: 39235967
    [No Abstract]   [Full Text] [Related]  

  • 30. CFTR modulator use in post lung transplant recipients.
    Benninger LA; Trillo C; Lascano J
    J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimation of Chloride Channel Residual Function and Assessment of Targeted Drugs Efficiency in the Presence of a Complex Allele [L467F;F508del] in the
    Efremova A; Melyanovskaya Y; Krasnova M; Voronkova A; Mokrousova D; Zhekaite E; Bulatenko N; Makhnach O; Bukharova T; Kutsev S; Goldshtein D; Kondratyeva E
    Int J Mol Sci; 2024 Sep; 25(19):. PubMed ID: 39408749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting.
    Daccò V; Rosazza C; Mariani A; Rizza C; Ingianni N; Nazzari E; Terlizzi V; Blasi FA; Alicandro G
    Pediatr Pulmonol; 2024 Nov; 59(11):2792-2799. PubMed ID: 38869349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
    Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
    [No Abstract]   [Full Text] [Related]  

  • 34. CFTR modulators: transformative therapies for cystic fibrosis.
    Dwight M; Marshall B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):281-284. PubMed ID: 33506726
    [No Abstract]   [Full Text] [Related]  

  • 35. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
    Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
    J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis.
    Smith M; Ryan KJ; Gutierrez H; Sanchez LHG; Anderson JN; Acosta EP; Benner KW; Guimbellot JS
    J Cyst Fibros; 2022 Jan; 21(1):e8-e10. PubMed ID: 34130909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
    Hong E; Zampoli M; Beringer PM
    Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
    [No Abstract]   [Full Text] [Related]  

  • 38. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
    Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
    J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients.
    Uyttebroek S; Claeyssens C; Jorissen M; Dupont L; Van Gerven L
    Rhinology; 2024 Aug; 62(4):457-465. PubMed ID: 38530204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on
    Huang Y; Paul G; Lee J; Yarlagadda S; McCoy K; Naren AP
    Am J Respir Crit Care Med; 2021 Nov; 204(10):1231-1235. PubMed ID: 34379998
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.